Daryl Drummond

Chief Scientific Officer

Experienced Chief Scientific Officer with a demonstrated history of working in the biotechnology industry. Skilled in Biotechnology, Life Sciences, Technology Transfer, GMP, and Nanotechnology. Strong research and development professional who completed postdoctorate with the pioneer in the field of lipid-based drug delivery systems, Demetrious Papahadjopoulos. Inventor and key to the development of the commercial drug Onivyde (liposomal irinotecan), for metastatic pancreatic cancer, through its eventual FDA and EMA approval. Leading expert in the engineering and development of liposomal and lipidic nanoparticle (LNP) based therapeutics for small molecules and nucleic acids (eg. mRNA), respectively, including the entry of six therapeutics and imaging agents into the clinic.

Talks About
#Biotechnology #DrugDelivery #Nanotechnology

Preferred Locations
#NorthAmerica